Tetrahydrocurcumin Chemosensitizes Breast Cancer to Albumin-Bound Paclitaxel by Enhancing SPARC Expression through Demethylation
In this study, we aimed to explore whether a natural compound, tetrahydrocurcumin (THC), could sensitize BC to albumin-bound paclitaxel (ab-PTX). The in vitro sensitization effect of THC to ab-PTX was evaluated in human BC cell lines, and in vivo chemosensitivity was measured using a xenograft BC tumor model. The expression of secreted protein acidic and rich in cysteine (SPARC), a speculated protein interacting with ab-PTX, was measured. Methylation-specific polymerase chain reaction (MSP) was used to further explore whether demethylation of SPARC by THC contributed to its chemosensitivity capabilities. Higher SPARC expre...
Source: Journal of Oncology - September 26, 2022 Category: Cancer & Oncology Authors: Dongjie Qiu Xiaolong Li Yinfeng Liu Xiaohuan Bao Li Ma Source Type: research
Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer
Biomed Res Int. 2022 Sep 13;2022:9430952. doi: 10.1155/2022/9430952. eCollection 2022.ABSTRACTBreast cancer (BC) is one of the most common malignancies affecting women and the leading cause of related mortality worldwide. An estimated 2260000 new cases of BC were diagnosed in 2020, which have seriously threatened the health. Paclitaxel (PTX), a natural product isolated from the bark of the pacific yew, has been found to be effective in treating advanced BC. Chemotherapy-induced peripheral neuropathy (CIPN), which refers to the damage to the peripheral nerves caused by exposure to a neurotoxic chemotherapeutic agent, is a c...
Source: Biomed Res - September 23, 2022 Category: Research Authors: Qie Guo Haonan Zhang Xiao Li Xianghua Quan Source Type: research
Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer
Biomed Res Int. 2022 Sep 13;2022:9430952. doi: 10.1155/2022/9430952. eCollection 2022.ABSTRACTBreast cancer (BC) is one of the most common malignancies affecting women and the leading cause of related mortality worldwide. An estimated 2260000 new cases of BC were diagnosed in 2020, which have seriously threatened the health. Paclitaxel (PTX), a natural product isolated from the bark of the pacific yew, has been found to be effective in treating advanced BC. Chemotherapy-induced peripheral neuropathy (CIPN), which refers to the damage to the peripheral nerves caused by exposure to a neurotoxic chemotherapeutic agent, is a c...
Source: Biomed Res - September 23, 2022 Category: Research Authors: Qie Guo Haonan Zhang Xiao Li Xianghua Quan Source Type: research
Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer
Biomed Res Int. 2022 Sep 13;2022:9430952. doi: 10.1155/2022/9430952. eCollection 2022.ABSTRACTBreast cancer (BC) is one of the most common malignancies affecting women and the leading cause of related mortality worldwide. An estimated 2260000 new cases of BC were diagnosed in 2020, which have seriously threatened the health. Paclitaxel (PTX), a natural product isolated from the bark of the pacific yew, has been found to be effective in treating advanced BC. Chemotherapy-induced peripheral neuropathy (CIPN), which refers to the damage to the peripheral nerves caused by exposure to a neurotoxic chemotherapeutic agent, is a c...
Source: Biomed Res - September 23, 2022 Category: Research Authors: Qie Guo Haonan Zhang Xiao Li Xianghua Quan Source Type: research
Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis
CONCLUSION: PD-1/PD-L1, Bev, ZOL, and Pt+ PARPi-containing regimens improved the pCR rate compared to traditional chemotherapy, including anthracyclines and taxanes. Chemotherapy with platinum salts or Nab-p improved the pCR rate. Nevertheless, the balance between efficacy and toxicity should be evaluated rigorously. PD-1/PD-L1-containing regimens appear to be the most favorable for TNBC neoadjuvant therapy, with good efficacy and tolerance.PMID:36103214 | DOI:10.1080/14737140.2022.2125381 (Source: Expert Review of Anticancer Therapy)
Source: Expert Review of Anticancer Therapy - September 14, 2022 Category: Cancer & Oncology Authors: Yushuai Yu Jie Zhang Yuxiang Lin Shaohong Kang Xinyin Lv Chuangui Song Source Type: research
A case of multiple primary lung adenocarcinoma with a CD74 ‐NRG1 fusion protein and HER2 mutation benefit from combined target therapy
Fig 1A shows the course of treatment for the patient in this case report. The patient underwent video-assisted thoracoscopic (VATS) right upper lobectomy with mediastinal lymph node dissection in November 2020. And then she received 2 cycles of pemetrexed and carboplatin from January 2021 to February 2021. Because the needle biopsy of the left lower lobe lesion showed adenocarcinoma, she underwent Cyberknife treatment in June 2021. After the diagnosis of stage IV lung adenocarcinoma with pleural metastasis, she was treated with of atezolizumab plus albumin-bound paclitaxel and carboplatin for 2 cycles from August 2021 to S...
Source: Thoracic Cancer - September 13, 2022 Category: Cancer & Oncology Authors: Kai Chen,
Wen Li,
Xiaoming Xi,
Jia Zhong Tags: CASE REPORT Source Type: research
Successful treatment of metastatic vulvar malignant melanoma with toripalimab: A rare case report and review of the literature
Rationale:
Vulvar melanoma is a rare and aggressive tumor with a high risk of local recurrence and distant metastasis. The prognosis is poor with a 5-year overall survival rate of only 46.6%. Management of vulvar melanoma remains a clinical challenge. Recent evidences have shown that immune checkpoint inhibitors are effective in the treatment of vulvar melanoma.
Patient concerns and diagnoses:
A 63-year-old woman with vulvar malignant melanoma suffered inguinal lymph node metastasis after vulvectomy and chemotherapy. She underwent inguinal lymph node dissection and inguinal radiotherapy. The tumor progressed aga...
Source: Medicine - September 9, 2022 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Molecules, Vol. 27, Pages 5648: Drugs That Changed Society: Microtubule-Targeting Agents Belonging to Taxanoids, Macrolides and Non-Ribosomal Peptides
During a screening performed by the National Cancer Institute in the 1960s, the terpenoid paclitaxel was discovered. Paclitaxel expanded the treatment options for breast, lung, prostate and ovarian cancer. Paclitaxel is only present in minute amounts in the bark of Taxia brevifolia. A sustainable supply was ensured with a culture developed from Taxus chinensis, or with semi-synthesis from other taxanes. Paclitaxel is marketed under the name Taxol. An intermediate from the semi-synthesis docetaxel is also used as a drug and marketed as Taxotere. O-Methylated docetaxel is used for treatment of some paclitaxel-resistant ...
Source: Molecules - September 1, 2022 Category: Chemistry Authors: S øren Brøgger Christensen Tags: Review Source Type: research
Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer: protocol of a single-centre, phase II clinical trial
This study is a single-centre, phase II trial. Patients with LAPC are randomly allocated to receive SBRT with BED10 of 60–70 Gy or >70 Gy in 5–6 fractions combined with gemcitabine plus albumin-bound paclitaxel. The primary outcome is progression-free survival. The secondary outcomes are adverse events, local control and overall survival.
Ethics and dissemination
The trial protocol has been approved by the Ethics committee of Shanghai Changhai Hospital. The ethics number is CHEC2020-100. Study results will be disseminated through peer-reviewed journals and released in related medical conferences.
Trial reg...
Source: BMJ Open - August 29, 2022 Category: General Medicine Authors: Ye, Y., Zhu, X., Zhao, X., Jiang, L., Cao, Y., Zhang, H. Tags: Open access, Oncology Source Type: research
Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report
ConclusionSince alectinib can occasionally cause drug-induced interstitial lung disease, as in the present case, lorlatinib may be an option to continue treatment in patients without other treatment alternatives. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - August 24, 2022 Category: General Medicine Source Type: research
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302)
CONCLUSIONS: The primary endpoint was achieved. Nab-paclitaxel was well tolerated and showed anti-tumor activity in patients with previously treated NSCLC. This study demonstrates a low degree of concordance in CIPN grading between physicians and patients.TRIAL REGISTRATION: University hospital Medical Information Network Clinical Trial Registry (ID: UMIN000012343).PMID:35958345 | PMC:PMC9359941 | DOI:10.21037/tlcr-22-89 (Source: Cell Research)
Source: Cell Research - August 12, 2022 Category: Cytology Authors: Satoshi Shoji Satoru Miura Satoshi Watanabe Aya Ohtsubo Koichiro Nozaki Yu Saida Kosuke Ichikawa Rie Kondo Tomohiro Tanaka Kenichi Koyama Hiroshi Tanaka Masaaki Okajima Tetsuya Abe Takeshi Ota Takashi Ishida Masato Makino Akira Iwashima Kazuhiro Sato Naoy Source Type: research
CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Although combined treatment with gemcitabine and albumin-bound paclitaxel has improved the prognosis of PDAC, both intri... (Source: Journal of Experimental and Clinical Cancer Research)
Source: Journal of Experimental and Clinical Cancer Research - August 10, 2022 Category: Cancer & Oncology Authors: Siyuan Zeng, Bin Lan, Xiaofan Ren, Shuman Zhang, Daniel Schreyer, Markus Eckstein, Hai Yang, Nathalie Britzen-Laurent, Andreas Dahl, Debabrata Mukhopadhyay, David Chang, Isabella Kutschick, Susanne Pfeffer, Peter Bailey, Andrew Biankin, Robert Gr ützmann Tags: Research Source Type: research
CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer
CONCLUSIONS: Our findings support the application of CRISPR-Cas9 screening in identifying novel therapeutic targets and suggest new strategies for overcoming chemoresistance in pancreatic cancer.PMID:35945614 | DOI:10.1186/s13046-022-02443-w (Source: Cell Research)
Source: Cell Research - August 9, 2022 Category: Cytology Authors: Siyuan Zeng Bin Lan Xiaofan Ren Shuman Zhang Daniel Schreyer Markus Eckstein Hai Yang Nathalie Britzen-Laurent Andreas Dahl Debabrata Mukhopadhyay David Chang Isabella Kutschick Susanne Pfeffer Peter Bailey Andrew Biankin Robert Gr ützmann Christian Pila Source Type: research
Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with conventional taxanes in women with breast cancer: a systematic review and meta-analysis
DISCUSSION: The Nab-P in all stages of breast cancer patients had significantly better efficacy and tolerance than the conventional taxanes. Moreover, preventive strategies for reducing the incidence of Nab-P induced sensory neuropathy should be explored in future studies.PMID:35927773 | DOI:10.21037/apm-22-690 (Source: Cancer Control)
Source: Cancer Control - August 4, 2022 Category: Cancer & Oncology Authors: Lei Lei Rucheng Chen Lei Fan Weijun Zheng Xiaojia Wang Source Type: research
